Filing Flows › BioCorRx (BICX) › Q2 2025
BioCorRx (BICX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
BioCorRx (BICX) reported revenue of $178K for the second quarter 2025 (Q2 2025), up 44-fold from a year earlier and +32% from the quarter before. Operating margin was -793.3%, net loss $1.4M (772.7% of revenue).
BioCorRx, Q2 2025: revenue $178K (44× year over year), operating margin -793.3%, net loss $1.4M, operating cash flow −$126K. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $178K | +32% | 44× |
| Operating profit | −$1.4M | — | — |
| Net earnings | −$1.4M | — | — |
| Operating cash flow | −$126K | — | — |
What changed
Revenue was $178K in Q2 2025, up 4306% year over year and up 32% from the previous quarter.
Operating costs exceeded revenue by $1.4M, an operating margin of -793.3%. Total costs grew 16% against revenue growth of 4306%. The fastest-growing cost line was Other operating costs (+972%). The quarter ended with a net loss of $1.4M, wider than the previous quarter's $852K loss. Minority interests bore $144K of it: to shareholders the quarter was a loss of $1.2M.
Operating cash flow was −$126K. Non-cash charges added back $72K of depreciation and amortization and $156K of share-based compensation. Working capital and other items added $1.0M.
Questions
What was BioCorRx's revenue in the second quarter 2025?
BioCorRx (BICX) reported revenue of $178K for the second quarter 2025 (Q2 2025), up 44-fold from a year earlier and +32% from the quarter before.
Was BioCorRx profitable in the second quarter 2025?
Operating loss was $1.4M (-793.3% of revenue) and net loss $1.4M.
Source: BioCorRx 10-Q on SEC EDGAR.